Innate Pharma (IPHA) Net earnings per share growth forecast for next year

Symbol and logo of brand Innate Pharma, S.A. (IPHA)

Innate Pharma S.A. (IPHA) revenues are based on grants and licenses, foreshadowing future sales growth in immunotherapy. On GURU.Markets, the trend in expected earnings per share reflects current trajectories, where the -232.10 metric determines the parameter status. Partnerships with tech giants ensure R&D stability, while outsourcing antibody production in France minimizes the company's operational risks.

IPHA - Innate Pharma, S.A. Earnings growth forecast for next year over the range 07/04/2022 - 11/12/2026

Metric breakdowns and analytics for innate-pharma.com (IPHA)

- price and consensus price forecast:
Price Chart Innate Pharma, S.A.|IPHA - Consensus Target
- market capitalization details:
Market Value Innate Pharma|IPHA - Real Price to Acquire Entire Company
- company book value details:
Accounting Value per Share Innate Pharma|IPHA - Book Capitalization|Market Value to Book Value Ratio innate-pharma.com|IPHA - Total Business Assets
- company liabilities and liquidity data:
Debt to Equity Innate Pharma S.A.|IPHA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Innate Pharma|IPHA - Company Total Indebtedness|Debt to Book Value Innate Pharma|IPHA - Amount of Long-Term Liabilities|Company Short-Term Debts Innate Pharma|Quick Ratio innate-pharma.com
- earnings and market ratios statistics:
IPHA - Company Net Income|Expected Profit Innate Pharma S.A.|IPHA - Company Value to Net Income|Forward P/E Multiple Innate Pharma S.A.|IPHA - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Innate Pharma|IPHA - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share for the last 12 months Innate Pharma|IPHA - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth innate-pharma.com|IPHA - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Innate Pharma S.A.
Analysis of all company metrics:Innate Pharma, S.A.
Core merchandise of Innate Pharma SA

This indicator measures the market's weighted average expectation for net earnings per share dynamics by aggregating daily analyst estimate revisions. For Innate Pharma S.A. (IPHA), this vector determines whether royalty payments from partners can offset oncology research costs. By analyzing the consensus for next year's earnings per share changes, an investor can identify shifts in the expected return. The resulting trajectory establishes a long-term benchmark for fundamental value.

Direct competitors

Net earnings per share growth forecast for next year ImmunityBio Corp|Expected earnings per share growth for next year Immunocore Corp (IMCR)|Net earnings per share growth forecast for next year Janux Therapeutics (JANX)|Expected earnings per share growth for next year arcusbio.com RCUS|Zymeworks - Expected earnings per share growth for next year|Earnings growth forecast for next year Tango Therapeutics Inc TNGX|IOVA - Net earnings per share growth forecast for next year|IMTX (Immatics Biotechnologies) - Projected earnings per share growth rate for next year|Xencor, Inc. (XNCR) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year compasstherapeutics.com (CMPX)|Expected earnings per share growth for next year REPL|LYEL - Net earnings per one share growth forecast for next year|Expected earnings per share growth for next year PYXS (Pyxis Oncology, Inc.)|Projected earnings per share increase next year CGEN|Earnings growth forecast for next year IOBT (IO Biotech, Inc.)|Expected earnings per share trend next year STRO|MiNK Therapeutics - Earnings growth forecast for next year|Expected net earnings per share growth next year Werewolf Therapeutics|immixbio.com (IMMX) - Net earnings per share growth forecast for next year|ALX Oncology Holdings Inc. - Expected earnings per share trend next year|CUE (Cue Biopharma, Inc.) - Earnings growth forecast for next year|Earnings growth forecast for next year PDS Biotechnology Corp|Net earnings per share growth forecast for next year Sonnet BioTherapeutics (SONN)|MAIA: Net earnings per share change forecast for next year|Liminatus Pharma Corp - Expected earnings per share growth for next year|LAVA Therapeutics NV (LVTX) - Expected net earnings per share growth next year|NextCure, Inc. - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year Leap Therapeutics, Inc. LPTX|intensitytherapeutics.com (INTS) - Net earnings per share growth forecast for next year|Projected earnings per share growth rate for next year SNSE|Net earnings per share growth forecast for next year Synthetic Biologics|Projected earnings per share growth rate for next year GRTS (Gritstone Bio)|Earnings growth forecast for next year KA|Earnings growth forecast for next year neximmune.com (NEXI)|Turnstone Biologics Corp. - Expected earnings per share growth for next year|Projected earnings per share increase next year VCNX (Vaccinex Inc.)|Harpoon Tx - Earnings growth forecast for next year